The association between first trimester placental biomarkers and placental lesions of maternal vascular malperfusion

• Published in: Placenta (Eastbourne) 2021-01, Vol.103, p.206-213
• Main Authors: Schiffer, V.M.M.M., Borghans, C.W.J., Arts, N., Bons, J.A.P., Severens-Rijvers, C.A.H., van Kuijk, S.M.J., Spaanderman, M.E.A., Al-Nasiry, S.
• Format: Article
• Language: English
• Subjects: Maternal vascular malperfusion; PAPP-A; Placental biomarkers; Placental syndrome; PlGF; sFlt-1
• ISSN: 0143-4004; 1532-3102
• DOI: 10.1016/j.placenta.2020.10.035

Abnormal levels of first trimester placental biomarkers are associated with the development of placental syndrome (PS). However, prediction performance is moderate, possibly explained by the clinical heterogeneity of PS. Aim of this study is to investigate the association between first trimester biomarkers and the presence of maternal vascular malperfusion (MVM), as a marker for placental insufficiency. This retrospective study included 195 women with available first trimester blood sample and placenta histological sections for examination at the Maastricht University Medical Centre. Women were divided into 4 groups, based on the presence of having MVM lesions and/or PS. Levels of PAPP-A, PlGF and sFlt-1 were measured and MVM lesions were classified according to the Amsterdam Placental Workshop Group Consensus Statement. MVM occurrence was observed in 32% of the uncomplicated pregnancies. Women with MVM (regardless of the PS) had lower levels of PAPP-A (p = 0.038) and sFLt-1 (p = 0.006), and a non-significant trend for lower PlGF and sFlt-1/PlGF ratio compared to women without MVM. Low PAPP-A levels individually and in combination with the presence of PS was significantly associated with MVM lesions (aOR = 3.0 and 6.1, respectively), as did the combination of low PlGF levels and PS (aOR = 4.6). In women with PS, having MVM increased the incidence of fetal growth restriction, small for gestational age neonates, lower birthweight and adverse neonatal outcome. Our findings suggest that MVM lesions were found to be associated with increased obstetric risks due to early placental dysfunction that can potentially be predicted by the use of first trimester biomarkers. •Lower levels of PAPP-A and PlGF are related to the presence of MVM lesions.•Low PAPP-A levels with placenta syndrome give a 6.1 higher odds on MVM lesions.•The presence of MVM lesions increases the incidence of adverse neonatal outcomes.•MVM lesions were observed in 32% of uncomplicated pregnancies.